Effects of angiotensin II receptor blockers on diabetic nephropathy

Journal of Hypertension

Volumn 27, Issue SUPPL. 5, 2009, Pages

  Kalaitzidis, Rigas ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Angiotensin II receptor blocker; Microalbuminuria; Nephropathy; Renin angiotensin system; Telmisartan

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; ISOPROSTANE DERIVATIVE; LISINOPRIL; LOSARTAN; METOPROLOL; NISOLDIPINE; PLACEBO; RAMIPRIL; SODIUM CHLORIDE; TELMISARTAN; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LONG TERM CARE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SODIUM INTAKE; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; PROTEINURIA;

EID: 70349277003     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000357904.71080.7d     Document Type: Review

References (53)

1. Maneia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano C, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
2. Chobanian A.V. Bakris G.L. Black H.R. Cushman W.C. Green L.A. Izzo J.L. Jr. Jones D.W. Materson B.J. Oparil S. Wright J.T. Jr. Roccella E.J. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 2003 42 6 1206-1252 DOI 10.1161/01.HYP.0000107251.49515.c2 2 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
3. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27 (Suppl 1):S79-S83.
4. Bakris G. Inclusion of albuminuria in hypertension and heart guidelines Kidney International, Supplement 2004 66 92 S124-S125 DOI 10.1111/j.1523-1755. 2004.09231.x, PII 4494972 4 Bakris G. Inclusion of albuminuria in hypertension and heart guidelines. Kidney int 2004; 66 (Suppl 92):S124-S125. (Pubitemid 43361449)
5. Bakris G.L. Clinical importance of microalbuminuria in diabetes and hypertension Current Hypertension Reports 2004 6 5 352-356 5 Bakris GL Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep 2004; 6:352-356. (Pubitemid 39359572)
6. Bigazzi R. Bianchi S. Baldari D. Campese V.M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension Journal of Hypertension 1998 16 9 1325-1333 DOI 10.1097/00004872-199816090-00014 6 Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325-1333. (Pubitemid 28408416)
7. Jager A. Kostense P.J. Ruhe H.G. Heine R.J. Nijpels G. Dekker J.M. Bouter L.M. Stehouwer C.D.A. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the hoorn study Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 3 617-624 7 Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscier Thromb Vase Biol 1999; 19:617-624. (Pubitemid 29135163)
8. Jensen J.S. Feldt-Rasmussen B. Strandgaard S. Schroll M. Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease Hypertension 2000 35 4 898-903 8 Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension microalbuminuria risk of ischemic heart disease. Hypertension 2000; 35:898-903. (Pubitemid 30303947)
9. Gerstein H.C. Mann J.F.E. Yi Q. Zinman B. Dinneen S.F. Hoogwerf B. Halle J.P. Young J. Rashkow A. Joyce C. Nawaz S. Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals Journal of the American Medical Association 2001 286 4 421-426 9 Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426. (Pubitemid 32681484)
10. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
11. Wachtell K. Ibsen H. Olsen M.H. Borch-Johnsen K. Lindholm L.H. Mogensen C.E. Dahlof B. Devereux R.B. Beevers G. De Faire U. Fyhrquist F. Julius S. Kjeldsen S.E. Kristianson K. Lederballe-Pedersen O. Nieminen M.S. Okin P.M. Omvik P. Oparil S. Wedel H. Snapinn S.M. Aurup P. Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study Annals of Internal Medicine 2003 139 11 901-906+I26 11 Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906. (Pubitemid 38124523)
12. De Leeuw P.W. Ruilope L.M. Palmer C.R. Brown M.J. Castaigne A. Mancia G. Rosenthal T. Wagener G. Clinical significance of renal function in hypertensive patients at high risk: Results from the INSIGHT trial Archives of Internal Medicine 2004 164 22 2459-2464 DOI 10.1001/archinte.164.22.2459 12 De Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Maneia G, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164:2459-2464. (Pubitemid 39628073)
13. Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008; 167:1226-1234.
14. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, lkehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69:1264-1271.
15. Arnlov J. Evans J.C. Meigs J.B. Wang T.J. Fox C.S. Levy D. Benjamin E.J. D'Agostino R.B. Vasan R.S. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The framingham heart study Circulation 2005 112 7 969-975 DOI 10.1161/CIRCULATIONAHA.105.538132 15 Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112:969-975. (Pubitemid 41170264)
16. Go A.S. Chertow G.M. Fan D. McCulloch C.E. Hsu C.-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization New England Journal of Medicine 2004 351 13 1296-1305+1370 DOI 10.1056/NEJMoa041031 16 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. W Engl J Med 2004; 351:1296-1300. (Pubitemid 39268908)
17. Festa A. D'Agostino R. Jr. Howard G. Mykkanen L. Tracy R.P. Haffner S.M. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study Kidney International 2000 58 4 1703-1710 DOI 10.1046/j.1523-1755.2000.00331.x 17 Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58:1703-1710. (Pubitemid 30739675)
18. Kistorp C. Raymond I. Pedersen F. Gustafsson F. Faber J. Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults Journal of the American Medical Association 2005 293 13 1609-1616 DOI 10.1001/jama.293.13.1609 18 Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293:1609-1615. (Pubitemid 40471791)
19. Wing Y.S. Kong A.P.S. Ma R.C.W. Ozaki R. Cheuk C.S. Chan N.N. Ng V. Chung S.H. Lam C.W.K. Chun C.C. Cockram C.S. Chan J.C.N. Tong P.C.Y. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients Diabetes Care 2006 29 9 2046-2052 http://care. diabetesjournals.org/cgi/content/full/29/9/2046 DOI 10.2337/dc06-0248 19 So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006; 29:2046-2053. (Pubitemid 44871185)
20. Ibsen H. Wachtell K. Olsen M.H. Borch-Johnsen K. Lindholm L.H. Mogensen C.E. Dahlof B. Devereux R.B. De Faire U. Fyhrquist F. Julius S. Kjeldsen S.E. Lederballe-Pedersen O. Nieminen M.S. Omvik P. Oparil S. Wan Y. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy Journal of Hypertension 2004 22 9 1805-1811 DOI 10.1097/00004872-200409000-00026 20 Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22:1805-1811. (Pubitemid 39141974)
21. Dahlof B. Devereux R.B. Kjeldsen S.E. Julius S. Beevers G. De Faire U. Fyhrquist F. Ibsen H. Kristiansson K. Lederballe-Pedersen O. Lindholm L.H. Nieminen M.S. Omvik P. Oparil S. Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Lancet 2002 359 9311 995-1003 DOI 10.1016/S0140-6736(02)08089-3 21 Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
22. Eijkelkamp W.B.A. Zhang Z. Remuzzi G. Parving H.-H. Cooper M.E. Keane W.F. Shahinfar S. Gleim G.W. Weir M.R. Brenner B.M. De Zeeuw D. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial Journal of the American Society of Nephrology 2007 18 5 1540-1546 DOI 10.1681/ASN.2006050445 22 Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18:1540-1546. (Pubitemid 46717521)
23. Kanno Y, Takenaka T, Nakamura T, Suzuki H. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 2006; 1:730-737.
24. Sarafidis P.A. Khosla N. Bakris G.L. Antihypertensive Therapy in the Presence of Proteinuria American Journal of Kidney Diseases 2007 49 1 12-26 DOI 10.1053/j.ajkd.2006.10.014, PII S027263860601612X 24 Sarafidis PA, Khosla N, Bakris GL Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49:12-26. (Pubitemid 44918179)
25. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol 2006; 1:229-235.
26. Bidani A. Controversy about COOPERATE ABPM trial data [1] American Journal of Nephrology 2006 26 6 629 DOI 10.1159/000098196 26 Bidani A. Controversy about COOPERATE ABPM trial data. Am J Nephrol 2006; 26:629-632. (Pubitemid 46143885)
27. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330:877-884.
28. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334:939-945.
29. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349:1857-1863.
30. Wright J.T. Jr. Bakris G. Greene T. Agodoa L.Y. Appel L.J. Charleston J. Cheek D. Douglas-Baltimore J.G. Gassman J. Glassock R. Hebert L. Jamerson K. Lewis J. Phillips R.A. Toto R.D. Middleton J.P. Rostand S.G. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial Journal of the American Medical Association 2002 288 19 2421-2431 DOI 10.1001/jama.288.19.2421 30 Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431. (Pubitemid 35340538)
31. Fan F.H. Zhang X. Guo H.Z. Xie D. Ping Y.C. Wei R.Z. Jian P.J. Liang M. Guo B.W. Zheng R.L. Ren W.G. Efficacy and safety of benazepril for advanced chronic renal insufficiency New England Journal of Medicine 2006 354 2 131-140 http://content.nejm.org/cgi/reprint/354/2/131.pdf DOI 10.1056/NEJMoa053107 31 Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354:131-140. (Pubitemid 43076710)
32. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
33. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, et al. Randomised controlled trial of enalapril and beta blockers in nondiabetic chronic renal failure. BMJ 1994; 309:833-837.
34. Bakris G.L. Copley J.B. Vicknair N. Sadler R. Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy Kidney International 1996 50 5 1641-1650 34 Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50:1641-1650. (Pubitemid 26364270)
35. Bakris G.L. Mangrum A. Copley J.B. Vicknair N. Sadler R. Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans Hypertension 1997 29 3 744-750 35 Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29:744-750. (Pubitemid 27097979)
36. Lewis E.J. Hunsicker L.G. Clarke W.R. Berl T. Pohl M.A. Lewis J.B. Ritz E. Atkins R.C. Rohde R. Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes New England Journal of Medicine 2001 345 12 851-860 DOI 10.1056/NEJMoa011303 36 Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860. (Pubitemid 34940824)
37. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
38. Estacio R.O. Jeffers B.W. Gifford N. Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 2000 23 SUPPL. 2 B54-B64 38 Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2): B54-B64. (Pubitemid 30185779)
39. Lea J. Greene T. Hebert L. Lipkowitz M. Massry S. Middleton J. Rostand S.G. Miller E. Smith W. Bakris G.L. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American study of kidney disease and hypertension Archives of Internal Medicine 2005 165 8 947-953 DOI 10.1001/archinte.165.8.947 39 Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, et al. The relationship between magnitude of proteinuria reduction and risk of endstage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165:947-953. (Pubitemid 40563243)
40. De Zeeuw D. Remuzzi G. Parving H.-H. Keane W.F. Zhang Z. Shahinfar S. Snapinn S. Cooper M.E. Mitch W.E. Brenner B.M. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL Kidney International 2004 65 6 2309-2320 DOI 10.1111/j.1523-1755.2004.00653.x 40 de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL Kidney Int 2004; 65:2309-2320. (Pubitemid 38670018)
41. Atkins R.C. Briganti E.M. Lewis J.B. Hunsicker L.G. Braden G. Champion De Crespigny P.J. Deferrari G. Drury P. Locatelli F. Wiegmann T.B. Lewis E.J. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy American Journal of Kidney Diseases 2005 45 2 281-287 DOI 10.1053/j.ajkd.2004.10.019 41 Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281-287. (Pubitemid 40431053)
42. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272-279.
43. Buter H. Hemmelder M.H. Navis G. De Jong P.E. De Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide Nephrology Dialysis Transplantation 1998 13 7 1682-1685 DOI 10.1093/ndt/13.7.1682 43 Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682-1685. (Pubitemid 28306794)
44. Weir MR, Fink JC. Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary. Am J Kidney Dis 2005; 45:176-188.
45. Laffer C.L. Bolterman R.J. Romero J.C. Elijovich F. Effect of salt on isoprostanes in salt-sensitive essential hypertension Hypertension 2006 47 3 434-440 DOI 10.1161/01.HYP.0000202480.06735.82, PII 0000426820060300000029 45 Laffer CL, Bolterman RJ, Romero JC, Elijovich F. Effect of salt on isoprostanes in salt-sensitive essential hypertension. Hypertension 2006; 47:434-440. (Pubitemid 43740287)
46. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19:999-1007.
47. Jones-Burton C. Mishra S.I. Fink J.C. Brown J. Gossa W. Bakris G.L. Weir M.R. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease American Journal of Nephrology 2006 26 3 268-275 DOI 10.1159/000093833 47 Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, et al. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol 2006; 26:268-275. (Pubitemid 44114397)
48. Nurkiewicz TR, Boegehold MA. High salt intake reduces endotheliumdependent dilation of mouse arterioles via superoxide anion generated from nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2006; 292:R1550-R1556.
49. Schmieder R.E. Delles C. Mimran A. Fauvel J.P. Ruilope L.M. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes Diabetes Care 2007 30 6 1351-1356 http://care.diabetesjournals.org/cgi/reprint/30/6/1351.pdf DOI 10.2337/dc06-1551 49 Schmieder RE, Delies C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30:1351-1357. (Pubitemid 46871137)
50. Makino H. Haneda M. Babazono T. Moriya T. Ito S. Iwamoto Y. Kawamori R. Takeuchi M. Katayama S. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes Diabetes Care 2007 30 6 1577-1578 http://care.diabetesjournals.org/cgi/reprint/30/6/1577.pdf DOI 10.2337/dc06-1998 50 Makino H, Haneda M, Babazono T, Moriya T, lto S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30:1577-1578. (Pubitemid 46871174)
51. Bakris G. Burgess E. Weir M. Davidai G. Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy Kidney International 2008 74 3 364-369 DOI 10.1038/ki.2008.204, PII KI2008204 51 Bakris G, Burgess E, Weir M, Davidai G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74:364-369. (Pubitemid 352002795)
52. Burnier M. Angiotensin Il type 1 receptor blockers. Circulation 2001; 103:904-912.
53. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet 2008; 372:511-512.